|1.||Xia, Bing: 2 articles (06/2015 - 10/2014)|
|2.||Qu, Fulian: 2 articles (06/2015 - 10/2014)|
|3.||Guo, Shanqi: 2 articles (06/2015 - 10/2014)|
|4.||Zhang, Yizhuo: 2 articles (06/2015 - 10/2014)|
|5.||Zhang, Qing: 2 articles (10/2014 - 04/2014)|
|6.||Johnson, Amy J: 2 articles (01/2012 - 09/2010)|
|7.||Byrd, John C: 2 articles (01/2012 - 09/2010)|
|8.||Lannutti, Brian J: 2 articles (09/2011 - 09/2010)|
|9.||Meng, Ling-hua: 1 article (10/2015)|
|10.||Ding, Jian: 1 article (10/2015)|
01/01/2012 - "However, additional studies are needed to prove CAL-101 is effective and safe as the goals of therapy for patients with lymphoid neoplasms are not only directed towards improving response and cure rates but also prolonging survival without affecting quality of life."
06/01/2014 - "The p110δ PI3K-selective compound CAL-101 (Idelalisib) did not inhibit markers of PI3K activity in cancer or stromal cells; however, unexpectedly, it induced phosphorylation on SQ motifs in both subpopulations of tumor cells in vivo but not in vitro. "
04/01/2014 - "This review focuses on the target, mechanism of action, the use and prospect of CAL-101 in tumors of blood and lymph systems. "
12/01/2011 - "As PI3Ks enter the arena of molecular-targeted therapies, CAL-101 provides proof of principle that isoform-selective compounds can be effective in selected cancer types and patient populations. "
04/01/2014 - "CAL-101 is a selective inhibitor of the phosphatidylinositol-3 kinase (PI3K), it inhibits the survival, proliferation and migration of tumor cells by directly inducing apoptosis and inhibiting micro-environmental interactions. "
|2.||Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
06/01/2015 - "The combination of CAL-101 and bortezomib is muchmore effective in inhibiting proliferation and promoting apoptosis of mantle cell lymphoma cell lines (Z138, HBL-2 and Jeko-1), which may be mediated through inhibiting PI3K/Akt signaling pathway and the transcription of NF-κB."
06/01/2015 - "To investigate the effect of CAL-101, a selective inhibitor of PI3Kδ, in combination with bortezomib on the proliferation and apoptosis in human mantle cell lymphoma cell lines Z138, HBL-2 and Jeko-1 in vitro, to explore its mechanisms and provide the foundation for effective treatment strategies against mantle cell lymphoma. "
|3.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
01/01/2014 - "In vivo, transient middle cerebral artery occlusion and reperfusion in kinase-dead PI3Kδ (p110δ(D910A/D910A)) or wild-type mice pre- or post-treated with the PI3Kδ inhibitor CAL-101, leads to reduced TNF levels, decreased leukocyte infiltration, reduced infarct size and improved functional outcome. "
|5.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
12/01/2011 - "Clinical studies of the drug CAL-101 have provided a significant advance by showing that selective targeting of PI3Kδ achieves efficacy in chronic lymphocytic leukemia, in part through targeting the tumor microenvironment."
01/01/2012 - "Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101)."
09/29/2011 - "The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia."
10/01/2015 - "The success of PI3K isoform-selective inhibitors is represented by CAL101 (Idelalisib), a first-in-class PI3Kδ-selective small-molecule inhibitor that has been approved by the FDA for the treatment of chronic lymphocytic leukemia, indolent B-cell non-Hodgkin's lymphoma and relapsed small lymphocytic lymphoma. "
09/23/2010 - "Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals."
|4.||Small Interfering RNA (siRNA)
|5.||Protein Isoforms (Isoforms)
|8.||2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidine
|1.||Molecular Targeted Therapy